Nexus Pharmaceuticals gets FDA nod for Arsenic Trioxide injection in 10mg per 10mL vial

Nexus Pharmaceuticals chief commercial officer Omair Ahmed said: “The approval of generic Arsenic Trioxide injection continues to show Nexus’s commitment in providing access to affordable critical-need generic injectables.

The post Nexus Pharmaceuticals gets FDA nod for Arsenic Trioxide injection in 10mg per 10mL vial appeared first on Pharmaceutical Business review.

BMS secures positive CHMP opinion for Opdivo- Yervoy combo in RCC

This recommendation will now be reviewed by the European Commission (EC), which has the authority to approve medicines for the European Union (EU). Bristol-Myers Squibb melanoma and genitourinary

The post BMS secures positive CHMP opinion for Opdivo- Yervoy combo in RCC appeared first on Pharmaceutical Business review.

Boehringer, Epizyme announce $300m oncology therapy program

As part of the collaboration worth $300m, Boehringer and Epizyme will involve in the research, development and commercialization of novel small molecule inhibitors directed toward two previously unaddressed

The post Boehringer, Epizyme announce $300m oncology therapy program appeared first on Pharmaceutical Business review.

Janssen applies for expanded approval for IMBRUVICA in Europe

One application seeks to include use of ibrutinib in combination with obinutuzumab in previously untreated adults with chronic lymphocytic leukaemia (CLL) and to add long-term follow-up data from

The post Janssen applies for expanded approval for IMBRUVICA in Europe appeared first on Pharmaceutical Business review.

Seattle Genetics begins blood cancer trial with SEA-BCMA

SEA-BCMA is an investigational antibody empowered using Seattle Genetics’ proprietary Sugar Engineered Antibody (SEA) technology designed to enhance antibody dependent cellular cytotoxicity. The target of SEA-BCMA, the cell

The post Seattle Genetics begins blood cancer trial with SEA-BCMA appeared first on Pharmaceutical Business review.

Merck’s Keytruda improves overall survival in phase 3 esophageal cancer trial

The phase 3 Keynote-181 study assessing Keytruda as monotherapy in the second-line treatment of advanced or metastatic esophageal or esophagogastric junction carcinoma has achieved a primary endpoint of

The post Merck’s Keytruda improves overall survival in phase 3 esophageal cancer trial appeared first on Pharmaceutical Business review.

AstraZeneca to sell Synagis US rights to Sobi for $1.5bn

Synagis is indicated for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncytial virus (RSV) in highly prone infants and is the only approved

The post AstraZeneca to sell Synagis US rights to Sobi for $1.5bn appeared first on Pharmaceutical Business review.

Scientists engineer DNA-encoded monoclonal antibodies for Zaire Ebolavirus

Study results, published online in Cell Reports, showed that DMAbs were expressed over a wide window of time and offered complete and long-term protection against lethal virus challenges.

The post Scientists engineer DNA-encoded monoclonal antibodies for Zaire Ebolavirus appeared first on Pharmaceutical Business review.

NextCure secures $93m funds to support clinical development of two drug candidates

The financing was led by Hillhouse Capital Management and Quan Capital, and included Bay City Capital, Surveyor Capital (a Citadel company), Ping An Ventures, Taiho Ventures LLC, ArrowMark

The post NextCure secures $93m funds to support clinical development of two drug candidates appeared first on Pharmaceutical Business review.

FDA grants priority review to Tecentriq for triple-negative breast cancer

The FDA designation for the Tecentriq chemo combination is for TNBC patients whose condition is unresectable locally advanced or metastatic and whose disease expresses the PD-L1 protein, as

The post FDA grants priority review to Tecentriq for triple-negative breast cancer appeared first on Pharmaceutical Business review.